Dr. Otegbeye is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-520-5000
Summary
- Folashade Otegbeye, MD, MPH is a skilled oncologist based in Seattle, WA. Her educational background includes a residency in Internal Medicine from Bridgeport Hospital/Yale University and a fellowship in Hematology and Medical Oncology from Case Western Reserve University/University Hospitals Cleveland Medical Center. She also holds an MPH from Harvard School of Public Health. Currently, she is an Associate Professor at Fred Hutch Cancer Center in Seattle, WA and attends on the Stem cell transplant and Cellular Immunotherapy services. Dr. Otegbeye possesses expertise in areas such as stem cell transplant, immunotherapy, cell and gene product manufacturing. She has produced numerous publications in her field, covering diverse topics ranging from natural killer cell research, to cell therapy manufacturing to standardization of nomenclature for cellular and genetic therapies. She has also coordinated clinical trials, including one related to an off-the-shelf NK cell platform and the preemptive infusion of donor lymphocytes.
Education & Training
- Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
- Bridgeport Hospital/Yale UniversityResidency, Internal Medicine, 2010 - 2013
- Harvard School of Public HealthMPH, 2008 - 2009
- Obafemi Awolowo University, Ile-IfeClass of 2005
Certifications & Licensure
- WA State Medical License 2021 - 2026
- OH State Medical License 2013 - 2022
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT Start of enrollment: 2024 Dec 01
Publications & Presentations
PubMed
- Development and validation of predictive models of early immune effector cell-associated hematotoxicity.Emily C Liang, Jennifer J Huang, Andrew J Portuguese, Valentín Ortiz-Maldonado, Aya Albittar
Blood Advances. 2025-02-11 - 6 citationsA multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia.Leland L Metheny, Ronald Sobecks, Christina Cho, Pingfu Fu, Seunghee Margevicius
Blood Advances. 2024-03-26 - Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies.Philip G Woost, Basem M William, Brenda W Cooper, Masumi Ueda Oshima, Folashade Otegbeye
Cytometry. Part B, Clinical Cytometry. 2024-01-01
Grant Support
- Research Training Award for FellowsAmerican Society of Hematology2015–2016
Professional Memberships
- Member
- Member
- Member
- American Society for Blood and Marrow TransplantationMember
- Society for Immunotherapy of CancerMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: